

Reykjavík, Monday, 07 April 2025

To: 25th WHO Expert Committee on Selection and Use of Essential Medicines
EML Secretariat
emlsecretariat@who.int

Subject: "A.19 Methylphenidate – attention deficit hyperactivity disorder"

This is a letter to confirm the board of ADHD samtökin fta [ADHD Iceland Association] supports the addition of methylphenidate-based medication to The WHO Essential Medicines List, as further detailed in: "A.19 Methylphenidate – attention deficit hyperactivity disorder."

ADHD medication based on the active ingrediency methylphenidate have long since been proven to be an effective option regarding treatment of ADHD, for both children and adults alike.

Considering the extensive research already available, we sincerely believe it is time to include methylphenidate in the WHO Model Lists of Essential Medicines (EML) and Essential Medicines for Children (EMLc).

Respectfully,



Vilhjalmur Hjalmarsson,
Chairman of ADHD samtökin fta
(ADHD Association Iceland)